Rice bran in ready-to-use therapeutic foods for microbiota-targeted treatment of childhood malnutrition

即用型治疗食品中的米糠用于针对儿童营养不良的微生物群治疗

基本信息

  • 批准号:
    10750478
  • 负责人:
  • 金额:
    $ 41.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-18 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Severe acute malnutrition (SAM) is the cause for nearly half of all child deaths under the age five. In Indonesia, SAM affects more than 2 million children and ~1% receive adequate treatment due to lack of access and coverage. Typical SAM treatment includes ready-to-use therapeutic foods (RUTF) which have shown immediate benefit and reduction in mortality rates, however, recovered children have persistent dysbiotic gut microbiota, leaving them susceptible to infection and malnutrition relapse as well as risk for chronic metabolic disease later in life. A growing focus has been placed on prebiotic foods in treatment of gut dysfunction, with little known regarding efficacy of prebiotic rich foods during SAM treatment and recovery. Rice bran contains prebiotics of growing significance to supporting favorable changes to commensal microbiota and microbiota metabolism. Rice Bran contains unique bioactive phytochemicals, lipids, and amino acids when compared to bran from other cereals. Compelling published and preliminary evidence from animals and humans support that rice bran positively influences the gut microbiome and metabolome for protection against diarrheal disease and supports healthy growth. Directed attention to improving SAM treatment of children with an innovative RUTF formulation containing rice bran is the basis for an ongoing double-blinded, randomized control trial (NCT05319717). This RCT is the first examination of rice bran during SAM treatment. The objective of this proposal is to examine whether the addition of rice bran to RUTFs results in changes to the recovering child’s microbiota and metabolism that provide enhanced protection against enteric infections, prevention of malnutrition relapse and promotion of blood metabolic profiles indicative of enhanced nutrient absorption. The hypothesis is that the RUTF + rice bran treatment will increase stool microbial diversity and favorably modulate the dried blood spot metabolome in SAM children when compared to a control RUTF. Dietary rice bran inclusion is expected to modulate both amino acid and lipid metabolism via gut microbiota in children recovered from SAM. Two proposed specific aims to explore this hypothesis are 1) Determine the effect of RUTF + rice bran on gut microbiota composition in the treatment of SAM compared to control RUTF in SAM in children ages 6-59 months and 2) Examine and establish EED marker and metabolite profiles associated with RUTF + rice bran in the treatment of SAM compared to control RUTF. Rice bran inclusion to RUTFs is anticipated to become a local, affordable solution that can enhance protection against microbial dysbiosis that is associated with malnutrition relapse, and results from stool and blood analysis will significantly advance our global knowledge of how to improve gut-directed SAM treatments.
项目概要 严重急性营养不良 (SAM) 是五岁以下儿童死亡中近一半的原因。在 印度尼西亚,SAM 影响了超过 200 万儿童,约 1% 的儿童由于缺乏 访问和覆盖范围。典型的 SAM 治疗包括即用型治疗食品 (RUTF),其具有 已显示出立竿见影的效果并降低了死亡率,但康复后的儿童仍持续存在 肠道微生物群失调,使它们容易受到感染和营养不良复发以及患 晚年慢性代谢性疾病。益生元食品在肠道治疗中的应用受到越来越多的关注 SAM 治疗和恢复期间富含益生元的食物的功效知之甚少。 米糠含有益生元,对于支持共生菌的有利变化具有越来越重要的意义 微生物群和微生物代谢。米糠含有独特的生物活性植物化学物质、脂质和氨基 与其他谷物的麸皮相比,酸含量更高。来自动物的令人信服的已发表证据和初步证据 人类支持米糠对肠道微生物组和代谢组产生积极影响以提供保护 对抗腹泻疾病并支持健康成长。重点关注改善 SAM 治疗 儿童使用含有米糠的创新 RUTF 配方是正在进行的双盲、 随机对照试验(NCT05319717)。该随机对照试验是首次在 SAM 处理期间对米糠进行检查。 该提案的目的是研究在 RUTF 中添加米糠是否会导致以下变化: 恢复儿童的微生物群和新陈代谢,增强对肠道感染的保护, 预防营养不良复发并促进表明营养增强的血液代谢特征 吸收。假设 RUTF + 米糠处理会增加粪便微生物多样性, 与对照 RUTF 相比,可有利地调节 SAM 儿童的干血斑代谢组。 膳食中米糠的添加有望通过肠道微生物群调节氨基酸和脂质代谢 从 SAM 中康复的儿童。探索该假设的两个提议的具体目标是 1) 确定 与对照 RUTF 相比,SAM 治疗组中 RUTF + 米糠对肠道微生物群组成的影响 6-59 个月儿童的 SAM 和 2) 检查并建立 EED 标记物和代谢物概况 与对照 RUTF 相比,在 SAM 处理中使用 RUTF + 米糠进行治疗。米糠夹杂物 RUTF 预计将成为一种本地的、负担得起的解决方案,可以增强对微生物的保护 与营养不良复发相关的菌群失调,粪便和血液分析的结果将显着 增进我们对如何改善肠道导向 SAM 治疗的全球知识。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth P Ryan其他文献

Elizabeth P Ryan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth P Ryan', 18)}}的其他基金

Dietary Rice Bran Phytochemicals and Microbial Metabolites for Colon Chemoprevent
用于结肠化学预防的膳食米糠植物化学物质和微生物代谢物
  • 批准号:
    8304033
  • 财政年份:
    2012
  • 资助金额:
    $ 41.66万
  • 项目类别:
Dietary Rice Bran Phytochemicals and Microbial Metabolites for Colon Chemoprevent
用于结肠化学预防的膳食米糠植物化学物质和微生物代谢物
  • 批准号:
    8517050
  • 财政年份:
    2012
  • 资助金额:
    $ 41.66万
  • 项目类别:
Probiotic Metabolism of Rice Bran Phytochemicals for Chemoprevention
米糠植物化学物质的益生菌代谢用于化学预防
  • 批准号:
    7897265
  • 财政年份:
    2010
  • 资助金额:
    $ 41.66万
  • 项目类别:
Probiotic Metabolism of Rice Bran Phytochemicals for Chemoprevention
米糠植物化学物质的益生菌代谢用于化学预防
  • 批准号:
    8053395
  • 财政年份:
    2010
  • 资助金额:
    $ 41.66万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了